Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, Piper Sandler lowered its price target on the stock from$70 to $52.
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, Piper Sandler lowered its price target on the stock from $70 to $52.
August 01, 2024 | 7:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics shares are trading lower due to worse-than-expected Q2 financial results. Piper Sandler also lowered its price target on the stock from $70 to $52.
The combination of disappointing Q2 financial results and a significant price target reduction by Piper Sandler is likely to negatively impact Sage Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100